Rock Springs Capital Management’s Janux Therapeutics JANX Stock Holding History

Rock Springs Capital Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.64M	Hold	367,009	–	–	0.28%	69
2026 Q1	$5.1M	Buy	367,009 +8,211	+2%	+$113K	0.3%	65
2025 Q4	$4.95M	Buy	358,798 +148,432	+71%	+$3.49M	0.25%	67
2025 Q3	$5.14M	Buy	210,366 +100	+0%	+$2.44K	0.3%	64
2025 Q2	$4.86M	Buy	210,266 +5,800	+3%	+$153K	0.3%	65
2025 Q1	$5.52M	Hold	204,466	–	–	0.32%	61
2024 Q4	$10.9M	Buy	+204,466	New	+$10.8M	0.42%	59

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Rock Springs Capital Management's JANX Position: Q2 2026 in Review

Rock Springs Capital Management held its Janux Therapeutics (JANX) position steady in Q2 2026 at 367,009 shares worth $5.64M. The position accounts for 0.28% of the portfolio, ranked #69.

Rock Springs Capital Management first reported a position in JANX in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.9M in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Rock Springs Capital Management held 367,009 shares of Janux Therapeutics worth $5.64M as of Q2 2026.
Rock Springs Capital Management left its Janux Therapeutics share count unchanged in Q2 2026.
Janux Therapeutics made up 0.28% of Rock Springs Capital Management's portfolio in Q2 2026, its #69 holding.
Rock Springs Capital Management first reported a position in Janux Therapeutics in Q4 2024 and has held it in 7 quarters since.
Rock Springs Capital Management's Janux Therapeutics position peaked at $10.9M in Q4 2024.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.